Cover Image
市場調查報告書

帕金森氏症:全球醫藥品產業、市場 (2016-2026年)

Parkinson's Disease: World Drug Industry and Market 2016-2026

出版商 Visiongain Ltd 商品編碼 220572
出版日期 內容資訊 英文 172 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
帕金森氏症:全球醫藥品產業、市場 (2016-2026年) Parkinson's Disease: World Drug Industry and Market 2016-2026
出版日期: 2016年05月16日 內容資訊: 英文 172 Pages
簡介

全球帕金森氏症治療藥的市場預計從2015年的32億1700萬美元,2020年達到34億7200萬美元的收益規模。

本報告提供全球帕金森氏症治療藥的市場調查,帕金森氏症與其治療相關概要,帕金森氏症治療藥的市場促進因素、阻礙要素分析,主要藥物類別概要,整體市場銷售額規模的變化與預測,主要產品的預測,主要國家市場的趨勢、預測,R&D狀況,定性分析,專家的採訪等彙整資料。

第1章 報告概要

第2章 與帕金森氏症其治療:簡介

  • 原因
  • 運動症狀
  • 神經精神病學症狀:在帕金森氏症患者中常見
  • 其他相關症狀
  • 診斷和治療

第3章 全球帕金森氏症治療藥市場預測

  • 全球帕金森氏症治療藥市場:整體市場銷售額預測
  • 帕金森氏症:市場區隔
  • 整體市場:商業性促進要素、阻礙要素
  • 多巴胺促效劑:帕金森氏症治療的基礎
  • 多巴胺受體激動劑:主要級
  • 兒茶酚-O-甲基轉移酵素 (COMT) 抑制劑:一般的選項
  • 單胺氧化酵素B (MAO-B) 抑制劑:比COMT好?

第4章 主要企業

  • Novartis的Stalevo/Comtan的銷售額
    • Stalevo/Comtan:市場預測
  • Teva的Azilect
    • Azilect:市場預測
  • UCB的Neupro貼片
    • Neupro:市場預測
  • 其他的企業

第5章 主要國家市場預測

  • 全球帕金森氏症治療藥市場:各地區明細
  • 全球帕金森氏症治療藥市場:各地區預測
  • 美國:單獨最大的市場
    • 市場預測
  • EU主要5個國家
    • 市場預測
    • 各國明細
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
  • 日本:65歲以上人口的比例是全球最高
    • 市場預測
  • 新興各國:巴西、俄羅斯、印度、中國 (金磚四國)
    • 金磚四國的收益成果:各國明細
    • 帕金森氏症藥的銷售額預測:各國
    • 巴西
    • 俄羅斯
    • 印度
    • 中國

第6章 帕金森氏症治療的R&D

  • 後期階段的研發產品線:新的作用機制
  • 階段IV研究:成藥的可能性擴大
  • 階段III臨床產品:前景看好
  • 階段II開發平台:概要
  • 階段I、前臨床開發平台:概要
  • 神經保護藥帶來的希望
  • 遺傳基因療法:有前途的研究、技術
  • International Stem Cell公司的單為生殖幹細胞:有前途的帕金森氏症技術

第7章 定性分析

  • SWOT分析
  • STEP分析

第8章 調查採訪

第9章 總論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0117

Parkinson's Diseases: World Drug Industry and Market 2016-2026 - our new study reveals trends, R&D progress, and predicted revenues

Our new report discusses issues and events affecting the Parkinson's disease therapeutics market. Our new report provides qualitative analyses to answer these key questions:

  • How is the Parkinson's disease therapeutics market evolving?
  • What is driving and restraining the Parkinson's disease therapeutics market?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • Who are the leading Parkinson's disease therapeutics companies, and what are their prospects over the forecast period?
  • What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?

Forecasts from 2016-2026 and other analyses show you commercial prospects

Our new report provides quantitative analyses to answer these key questions:

  • What are the market shares of the Parkinson's therapeutics disease market in 2015?
  • How will each of the drugs in the Parkinson's therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2026?
  • What Parkinson's disease drugs are in the development pipeline?
  • How will each of Parkinson's disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2026?
  • How will the market shares of the national markets change by 2026 and which geographical region will lead the market in 2026?

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales.

Many opportunities exist for the treatment of Parkinson's. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead.

image1

Discover sales predictions for the world market and submarkets

Discover in our report overall world revenue to 2026 for Parkinson's disease medicines. Also explore individual revenue predictions to 2026 for five therapeutic submarkets at world level:

  • Dopaminergic Agents
  • Dopamine Receptor Agonists
  • MAO-inhibitors
  • COMT-inhibitors
  • Other Therapeutic Options

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for Parkinson's disease drugs

How will individual medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of three brands sold by four companies:

  • Neupro (UCB)
  • Azilect (Teva)
  • Azilect (Lundbeck)
  • Comtan/Stalevo (Novartis)

What are the prospects in the leading regions and countries?

Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2015.

Our work also shows individual revenue forecasts to 2026 for 11 national markets:

  • United States (US)
  • Japan
  • EU leaders - Germany, France, the UK, Italy and Spain (EU5)
  • BRIC nations - Brazil, Russia, India and China

Leading companies and potential for market growth

In 2015 the overall world PD drug market generated $3217m. Visiongain predicts its revenues in 2020 to reach $3472m. Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:

  • Novartis
  • Teva
  • UCB
  • Roche
  • Lundbeck

What affects producers of those medicines?

Our report discusses issues and events affecting that industry and market from 2015, including these:

  • Research and development (R&D) - drugs, diagnostic tests, and related technologies
  • Disease prevalence - expanding patient populations
  • Disease-modifying drugs and obstacles to cures
  • Regulatory guidelines - changes and opportunities.
  • Drugs and related technologies to transform the market
  • Biomarkers
  • Deep brain stimulation (functional neuromodulation)
  • Intellectual property (IP), licensing agreements and partnerships.

Our 172-page report provides 120 charts. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.

Benefit your work now through our updated study, gaining original industry and market analysis:

  • Revenues for Parkinson's disease treatments to 2026 - assess that overall world drugs market's potential and get forecasted revenues for the five leading sub-classes: dopaminergic agents, dopamine receptor agonists, COMT- and MAO-inhibitors and other therapeutic options.
  • Products' sales to 2026 - discover predicted revenues Neupro, Comtan/Stalevo, and Azilect and see how those medicines can compete and succeed
  • National market forecasting to 2026 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and growth
  • R&D activities - see progress, trends and prospects in research and development, finding technological, clinical and commercial possibilities
  • Companies, news and opinions - examine participants, including Roche, Novartis, UCB and Lundbeck and get two exclusive interviews, helping your reputation for insight and staying ahead. Visiongain interviewed:
    • Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US
    • Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York.
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

Table of Contents

1. Report Overview

  • 1.1 Overview of Findings: World Market Overview 2015 to 2026
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers: Chapter Outlines
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who is This Study For?
  • 1.6 Research and Analysis Methods
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About visiongain

2. Introduction to Parkinson's Disease and its Treatments

  • 2.1 What Causes Parkinson's?
  • 2.2 Motor Symptoms of Parkinson's Disease
    • 2.2.1 Tremor: The First Sign of PD
    • 2.2.2 Uncontrolled Muscle Contractions Cause Rigidity
    • 2.2.3 Bradykinesia: The Most Characteristic Feature of Parkinson's
    • 2.2.4 Postural Instability Manifests as PD Progresses
  • 2.3 Neuropsychiatric Symptoms are Common in PD Patients
    • 2.3.1 Behavioural Deficits are Often the Most Widespread
    • 2.3.2 Cognitive Impairment can Impede Daily Tasks
    • 2.3.3 Autonomic Dysfunction: Another Common Occurrence
  • 2.4 Other Symptoms Associated with Parkinson's
  • 2.5 Parkinson's Disease: Diagnosis and Treatment
    • 2.5.1 Diagnosis is Difficult
    • 2.5.2 Treatment Options - Therapeutic Classes

3. Parkinson's Disease: World Drugs Market, 2016-2026

  • 3.1 Sales of the Overall World PD Drugs Market, 2015-2026
  • 3.2 Parkinson's Disease: Market Segmentation, 2015
  • 3.3 Overall PD Drug Market: Commercial Drivers and Restraints
  • 3.4 Dopaminergic Agents: Foundation of PD Treatment
    • 3.4.1 Levodopa Therapy
    • 3.4.2 Patent Expiries Affect the Market
    • 3.4.3 New Levodopa Therapies on the Horizon
    • 3.4.4 Dopaminergic Agents: Market Projections to 2026
  • 3.5 Dopamine Receptor Agonists: The Leading Class in 2016
    • 3.5.1 Dopamine Agonists: A Front Line Drug
    • 3.5.2 Advantages over L-Dopa Therapy
    • 3.5.3 Leading Drugs in the Segment
    • 3.5.4 A Healthy R&D Pipeline
    • 3.5.5 Dopamine Receptor Agonists: Market Projections, 2016-2026
  • 3.6 Catechol-O-Methyl Transferase (COMT) Inhibitors: A Popular Choice of Treatment
    • 3.6.1 Entacapone: The Leading Drug in this Segment
    • 3.6.2 Commercial Scope for COMT Inhibitors
    • 3.6.3 COMT Inhibitors: Market Projections, 2016-2026
  • 3.7 Are Monoamine Oxidase-B (MAO-B) Inhibitors Better Than COMT?
    • 3.7.1 MAO-B Inhibitor Therapeutics in the Market
    • 3.7.2 New MAO-B Products in Development
    • 3.7.3 MAO-B Inhibitors: Market Projections, 2016-2026
    • 3.7.4 Other Therapeutic Options: A Growing Opportunity
    • 3.7.5 Generic Erosion in the PD Market
    • 3.7.6 A Broad and Diverse Pharmaceutical Segment
    • 3.7.7 Other Non-medication PD Therapies
    • 3.7.8 The Pipeline Offers Disease Modifying Potential
    • 3.7.9 Other Mechanisms of Action: Market Projections, 2016-2026

4. Leading Companies in the PD Drug Market, 2016

  • 4.1 PD: Novartis sales of Stalevo/Comtan
    • 4.1.1 Market Forecast for Comtan/Stalevo, 2016-2026
  • 4.2 Teva's Azilect: Past, Present and Future
    • 4.2.1 Market Forecast for Azilect, 2015-2026
  • 4.3 UCB's Leading Neupro Patch Drug
    • 4.3.1 Market Forecast for Neupro, 2016-2026
  • 4.4 Other Market Players

5. The Leading National Markets, 2016-2026

  • 5.1 Regional Breakdown of the World PD Drug Market, 2016
  • 5.2 The World PD Drug Market: Regional Forecasts to 2026
  • 5.3 The PD Drug Market in the US: The Largest Single National Market
    • 5.3.1 Market Projections for the US, 2015-2026
  • 5.4 The PD Drug Market in the Five Leading European National Markets (EU5), 2016-2026
    • 5.4.1 Market Projections for the EU5, 2016-2026
    • 5.4.2 EU5 Breakdown by Country, 2016
    • 5.4.3 Market Projection for EU5 Countries, Regional Breakdown
    • 5.4.4 Germany: The Largest EU5 Market
    • 5.4.5 France: Strong Healthcare System - What's Possible There?
    • 5.4.6 UK's Spending Restrictions Affect the PD Drugs Market
    • 5.4.7 Spain - What Effects Will Austerity Have on PD Drug Sales?
    • 5.4.8 The PD Drug Market in Italy: Rising and Ageing Population
  • 5.5 Japan has the Highest Proportion of Over-65s in the World
    • 5.5.1 Predictions for Japanese PD Drug Market, 2016-2026
  • 5.6 PD Drug Market in Emerging Countries: Brazil, Russia, India and China (BRIC)
    • 5.6.1 Breakdown of BRIC Revenues by Country, 2016
    • 5.6.2 Market Projections for BRIC Nations' PD Drug Sales, 2016-2026
    • 5.6.3 Brazil's Rapid Growth of the Pharma Market - What's the Future?
    • 5.6.4 Russia's Healthcare Market Gives Generic Sales Opportunities
    • 5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market
    • 5.6.6 China's Ageing Population Stimulates Sales of PD-Treating Medicines

6. Research and Development for Treating Parkinson's Disease

  • 6.1 New Mechanisms of Action in the Late-Stage R&D Pipeline
  • 6.2 Growing Potential of Marketed Products: Phase IV Studies
  • 6.3 Phase III Clinical Products Promising Potential in the PD market
    • 6.3.1 IPX203 (Impax Laboratories): The New Generation of Levodopa
    • 6.3.2 Newron's Safinamide Expected Launch in 2020
    • 6.3.3 Pimavanserin: A First-in-Class Treatment for Parkinson's Disease Psychosis
    • 6.3.4 Istradefylline: A Promising A(2a) Receptor Antagonist
    • 6.3.5 Termination of Preladenant, APromising A(2a) Receptor Antagonist
    • 6.3.6 Levodopa/Carbidopa Intestinal Gel (LCIG)
    • 6.3.7 Can Opicapone Compete with Existing COMT Inhibitors
    • 6.3.8 Pitolisant: Addressing an Unmet Need
    • 6.3.9 Northera: Oral Precursor of Norepinephrine
    • 6.3.10 Targin by Mundipharm
    • 6.3.11 Nurelinfor Levodopa-Induced Dyskinesia
    • 6.3.12 SYN-115/120: Superior to Istradefylline?
  • 6.4 Phase II PD Pipeline: Overview
    • 6.4.1 Glutamatergic Drugs: Main Target for Pipeline Candidates
    • 6.4.2 Fipamezole: Another Promising A(2a) Receptor Antagonist
    • 6.4.3 CVT-301: A Novel Intrapulmonary Approach
    • 6.4.4 DM-1992: Can Compete with Levodopa Reformulations?
    • 6.4.5 The Accordion Pill Carbidopa/Levodopa by Intec Pharma
    • 6.4.6 Orient Addresses Sialorrhoea
    • 6.4.7 NH004: Formulated with a Muco-Adhesive Property
    • 6.4.8 VR040: A Reformulation of Apomorphine
    • 6.4.9 AVP-923: A Novel Approach for LID-PD
    • 6.4.10 PD Giant Orion, Develop a New Levodopa Drug, ODM-101
    • 6.4.11 News for NeuroDerm's Reformulations
  • 6.5 Phase I and Pre-clinical PD Pipeline: Overview
    • 6.5.1 Vernalis' A(2a) Receptor Antagonist Drug in Phase Ib/IIa
    • 6.5.2 Sanofi Collaborates with The Michael J. Fox Foundation
    • 6.5.3 UCL Show Exenatide Potential in Parkinson's
    • 6.5.4 Titan Pharmaceuticals Develop a Novel Platform
  • 6.6 Neuroprotective Drugs Offer Hope
    • 6.6.1 Phytopharm and Cogane Development
    • 6.6.2 The Potential of Dietary Supplements
    • 6.6.3 GCase Enzymes: Amicus and Biogen Strike A Deal for Parkinson's
    • 6.6.4 Research Finds Ursodeoxycholic Acid (UDCA) A Potential Cure for Parkinson's
    • 6.6.5 PD Biomarkers: Potential for Revolutionising Diagnosis and Treatment
    • 6.6.6 Antibody Targeting: The Coming of Age
  • 6.7 Gene Therapy: Promising Research and Technology
    • 6.7.1 ProSavin: Leading Gene Therapy Product
    • 6.7.2 CERE-120 Promises Repair of Damaged Dopaminergic Neurons
    • 6.7.3 AAV-hAADC-2: Another Gene Therapy Contender
  • 6.8 Parthenogenesis (International Stem Cell Corporation): A Promising Outlook for PD Technology

7. Qualitative Analysis of the PD Drug Market, 2016

  • 7.1 SWOT Analysis of the PD Market
    • 7.1.1 Strengths and Weaknesses in the PD Drug Industry in 2016
    • 7.1.2 Opportunities and Threats There from 2016 Onwards
  • 7.2 STEP Analysis of the PD Market
    • 7.2.1 Social Implication of Living with PD
    • 7.2.2 Technological Developments on the Horizon
    • 7.2.3 Economic Pressures: Healthcare Budgeting
    • 7.2.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways

8. Research Interviews

  • 8.1 Interview with Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US
    • 8.1.1 The Overall PD Market
    • 8.1.2 Current Understanding of Stem Cell Therapy
    • 8.1.3 ISCO's Novel PD Programme
    • 8.1.4 The Potential of Immune-Matching
    • 8.1.5 The Controversy Surrounding Stem Cell Research
    • 8.1.6 The Potential for Parthenogenesis in PD and Other Applications
  • 8.2 Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York
    • 8.2.1 A possible Cure
    • 8.2.2 Future Potential: Research

9. Conclusions from the Research and Analysis

  • 9.1 The World PD Market: Predictions to 2026
  • 9.2 Which Therapeutic Class will Dominate the Market in 2026?
  • 9.3 Disease Modification: The Ultimate Goal
  • 9.4 The Future of the Industry and Market for Parkinson's Medicines
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 1.1 Parkinson's disease Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2016-2026
  • Table 1.2 Currency Exchange Rates, 2016
  • Table 2.1 Overview of the Therapeutic Drug Classes for PD, 2015
  • Table 3.1 World Parkinson's Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 3.2 World Parkinson's Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 3.3 PD Market Segmentation, Revenues ($m), Market Shares (%), 2016
  • Table 3.6 Formulations of Levodopa Therapy, 2016
  • Table 3.7 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 3.8 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 3.9 Overview of Therapeutic Drug Classes in PD Therapy, 2016
  • Table 3.10 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 3.11 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 3.12 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 3.13 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 3.14 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR(%), Market Share (%), 2015-2020
  • Table 3.15 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR(%), Market Share (%), 2021-2026
  • Table 3.16 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 3.17 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 4.1 Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
  • Table 4.2 Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.3 Teva's Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
  • Table 4.3.1 Teva's Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.4 Lundbeck's Azliect Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
  • Table 4.4.1 Lundbeck's Azliect Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.5 UCB's Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2020
  • Table 4.5.1 UCB's Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 5.2 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.3 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.4 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.5 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.6 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.7 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.8 EU5 Regional Breakdown by Country, Revenues ($m), Market Share (%), 2016
  • Table 5.9 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.10 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.11 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.12 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.13 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.14 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.15 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.16 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.17 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.18 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.19 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.20 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.21 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.22 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.23 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.24 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.25 BRIC Regional Breakdown by Country, Revenues ($m),BRIC Market Shares (%), 2016
  • Table 5.26 BRIC PD Drug Market Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.27 BRIC PD Drug Market Breakdown Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.28 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.29 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.30 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.31 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.32 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.33 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.34 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.35 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 6.1 Late-Stage PD Pipeline, 2016
  • Table 6.2 Reformulations of Levodopa and Other Dopaminergic Agents in Development, 2013
  • Table 6.3 Phase II PD Pipeline, 2016
  • Table 6.4 Glutamatergic PD Pipeline, 2016
  • Table 6.5 Early-Stage Developments for PD, 2013
  • Table 6.6 Selected Gene Therapies in the PD Pipeline, 2015
  • Table 7.2 Parkinson's Disease Drug Market: Opportunities and Threats, 2016-2026
  • Table 7.3 PD Drug Market: STEP Analysis, 2016

List of Figures

  • Figure 1.1 Global Parkinson's disease Market Segmentation Overview, 2015
  • Figure 3.2 PD Market Segmentation ($m), Market Shares (%), 2016
  • Figure 3.3 PD Drug Market Breakdown by Segment, Revenues ($m), 2015-2026
  • Figure 3.4 PD Drug Market, Drivers and Restraints, 2015-2026
  • Figure 3.5 Dopaminergic Agents Segment Forecast, Revenues ($m), 2015-2026
  • Figure 3.6 Dopaminergic Agents Market: Drivers and Restraints, 2016-2026
  • Figure 3.7 Dopaminergic Receptor Agonists Segment Forecast, Revenues ($m), 2015-2026
  • Figure 3.8 Dopamine Receptor Agonists Market, Drivers and Restraints, 2015-2026
  • Figure 3.9 COMT Inhibitors Segment Forecast, Revenues ($m), 2015-2026
  • Figure 3.10 COMT Inhibitors Market, Drivers and Restraints, 2015-2026
  • Figure 3.11 MAO Inhibitors Segment Forecast, Revenues ($m), 2015-2026
  • Figure 3.12 MAO Inhibitors Market, Drivers and Restraints, 2016-2026
  • Figure 3.13 Other Mechanisms of Action Segment Forecast, Revenues ($m), 2015-2026
  • Figure 3.14 Other Mechanisms of Action, Market Drivers and Restraints, 2015-2026
  • Figure 4.1 Revenues ($m) of Parkinson's Drugs by Leading Company, 2013-2015
  • Figure 4.2 Orion's Comtan/Stalevo Drug Revenues ($m) Forecast, 2014-2026
  • Figure 4.3 Teva's Azilect Drug Revenues Forecast, 2014-2026
  • Figure 4.3.1 Lundbeck's Azilect Drug Revenues Forecast, 2014-2026
  • Figure 5.1 PD Market Breakdown by Region, Market Shares (%), 2016
  • Figure 5.2 PD Drug Market Breakdown by Region, Revenues ($m), 2013-2026
  • Figure 5.3 US Over-65 Population as Percentage of Overall Population, 2015-2026
  • Figure 5.4 US PD Drug Market, Revenue Forecast ($m), 2015-2026
  • Figure 5.5 EU5 PD Drug Market, Revenue ($m), 2015-2026
  • Figure 5.6 EU5 Regional Breakdown by Country, Revenues ($m), Market Share(%), 2016
  • Figure 5.7EU5 Regional Breakdown by Country, Revenues ($m), 2015-2026
  • Figure 5.8 Over-65 Population in Germany as Percentage of Overall Population, 2015-2026
  • Figure 5.9 German PD Drug Market, Revenues ($m), 2015-2026
  • Figure 5.10 Over-65 Population in France as Percentage of Overall Population, 2015-2026
  • Figure 5.11 French PD Drug Market, Revenues ($m), 2015-2026
  • Figure 5.12 Over-65 Population in the UK as a Percentage of Overall Population, 2015-2026
  • Figure 5.13 UK PD Drug Market, Revenues ($m), 2015-2026
  • Figure 5.14 Over-65 Population in Spain as Percentage of Overall Population, 2015-2026
  • Figure 5.15 Spanish PD Drug Market, Revenues ($m), 2015-2026
  • Figure 5.16 Over-65 Population in Italy as Percentage of Overall Population, 2015-2026
  • Figure 5.17 Italian PD Drug Market, Revenues ($m), 2015-2026
  • Figure 5.18: Over-65 Population in Japan as Percentage of Overall Population, 2015-2026
  • Figure 5.19 Japanese PD Drug Market, Revenues ($m), 2015-2026
  • Figure 5.20 BRIC PD Drug Market, Revenue ($m), 2015-2026
  • Figure 5.21 BRIC Regional Breakdown by Country, Revenues ($m), BRIC Market Share (%), 2016
  • Figure 5.22 BRIC PD Drug Market Breakdown, Revenues ($m), 2015-2026
  • Figure 5.23 Brazilian PD Drug Market, Revenues ($m), 2015-2026
  • Figure 5.24 Russian PD Drug Market, Revenues ($m), 2015-2026
  • Figure 5.25 Indian PD Drug Market, Revenues ($m), 2015-2026
  • Figure 5.26 Chinese PD Drug Market, Revenues ($m), 2015-2026
  • Figure 8.1 Parthenogenesis Results in Cells Inheriting a Duplicate Set of HLA genes, which Reduces Immune Rejection
  • Figure 9.1 PD Drug Market, Overall Revenues ($m), 2015, 2020 and 2026
  • Figure 9.2 PD Drug Market by Segment, Revenues ($m), 2015, 2020 and 2026

Companies Listed

  • Abbott Laboratories
  • AbbVie Pharmaceuticals
  • Acadia Pharmaceuticals
  • Adamas Pharmaceuticals
  • Addex Therapeutics
  • Amgen
  • Amicus Therapeutics
  • AmarantusBioSciences
  • Amylin Pharmaceuticals
  • Ark Therapeutics
  • AstraZeneca
  • Avanir Pharmaceuticals
  • AxxonisPharma
  • BIAL - Portela
  • BiogenIdec
  • Bioprojet Pharma
  • Biotie Therapies
  • Biovail
  • BoehringerIngelheim
  • Cardiovascular and Renal Drug Advisory Committee
  • Ceregene
  • Chelsea Therapeutics
  • Civitas Therapeutics
  • Columbia University
  • Dainippon Sumitomo Pharma
  • Depomed
  • DiaGenic
  • Domain Therapeutics
  • Dr. Reddy'sLaboratories
  • Durin Technologies
  • Eisai
  • European Medicines Agency (EMEA/EMA)
  • Food and Drug Administration (US FDA)
  • Genzyme
  • GlaxoSmithKline (GSK)
  • ImpaxLaboratories
  • Intec Pharma
  • International Stem Cell Corporation
  • Ipsen
  • JuvantiaPharma
  • Kyowa Hakko Kirin
  • Lundbeck
  • Meiji Seika
  • Merck & Co.
  • Merck Serono
  • Mundipharma Research
  • Mylan
  • Napp Pharmaceuticals
  • National Health Service (NHS, UK)
  • National Institute for Health and Clinical Excellence (NICE, UK)
  • National Institute of Neurological Disorders and Stroke (NINDS, US)
  • National Institutes of Health (NIH, US)
  • Neuren Pharmaceuticals
  • Neuroderm
  • NeuroGeneration
  • NeuroHealing
  • Neurologix
  • Newron Pharmaceuticals
  • Novartis
  • NuroPro
  • Ono Pharmaceuticals
  • Orient Pharma
  • Orion
  • Otsuka Pharmaceuticals
  • Oxford BioMedica
  • Parkinson's UK
  • Par Pharmaceuticals
  • Pfizer
  • Pharmaceutical Research and Manufacturers Association
  • Phytopharm
  • Power3 Medical Products
  • Prothena Corporation
  • Roche
  • Roxane Laboratories
  • Sanofi
  • Santhera
  • Schering Plough
  • Sheffield Institute for Translational Neuroscience
  • SK Biosciences
  • Skye Pharma
  • Sun Pharmaceuticals
  • Technion-Israel Institute of Technology
  • Teva Pharmaceutical Industries
  • The Michael J. Fox Foundation
  • The Parkinson Study Group
  • Titan Pharmaceuticals
  • UCB
  • uniQure
  • University at Buffalo, the State University of New York
  • University College London (UCL)
  • Valeant
  • Varinel
  • Vectura Group
  • Vernalis
  • Watson Pharmaceuticals
  • Wockhardt
  • XenoPort
  • Zambon Group
Back to Top